IDP-wtLN10
General Information
DRACP ID DRACP01769
Peptide Name IDP-wtLN10
Sequence AAKVVILKKATEYVES
Sequence Length 16
UniProt ID Not available
PubChem CID Not available
Origin Synthetics
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients | Glioblastoma | Blastoma | EC50>100 μM | CYTELL assay | 72-96 h | Patent |
12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients | Glioblastoma | Blastoma | EC50>100 μM | CYTELL assay | 72-96 h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C80H137N19O24
Absent amino acids CDFGHMNPQRW
Common amino acids AKV
Mass 201682
Pl 9.22
Basic residues 3
Acidic residues 2
Hydrophobic residues 8
Net charge 1
Boman Index -899
Hydrophobicity 30
Aliphatic Index 121.88
Half Life
Mammalian: 1.4 hour
Yeast: 3 min
E.coli: >10 hour
Extinction Coefficient cystines 1490
Absorbance 280nm 99.33
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US2020/0157150A1
Patent Title Anticancer Peptides
Other Iinformation Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status: Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017
Other Published ID AU2018311129A1 CA3071601A1 CN111436200A EP3661947A1 JP2020529429A KR20200032730A WO2019025432A1